SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML
暂无分享,去创建一个
F. Ravandi | D. DeAngelo | J. Lancet | A. Fathi | A. Advani | T. Kovacsovics | R. Walter | H. Erba | D. Bixby | S. Faderl | E. Stein | A. Stein | A. Jillella | M. O'Meara | D. Kennedy